The global Cancer Biopsy market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
For most types of cancer, biopsy is the main way doctors diagnose cancer. A biopsy is a microscopic examination of a small amount of tissue. Other tests may indicate that cancer exists, but only biopsy can make a definite diagnosis.
Report includes an overview of the development of the Cancer Biopsy industry chain, the market status of Breast Cancer (Tissue Biopsies, Liquid Biopsies), Colorectal Cancer (Tissue Biopsies, Liquid Biopsies), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cancer Biopsy.
Regionally, the report analyzes the Cancer Biopsy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cancer Biopsy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Cancer Biopsy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cancer Biopsy industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Tissue Biopsies, Liquid Biopsies).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cancer Biopsy market.
Regional Analysis: The report involves examining the Cancer Biopsy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cancer Biopsy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Cancer Biopsy:
Company Analysis: Report covers individual Cancer Biopsy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cancer Biopsy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Breast Cancer, Colorectal Cancer).
Technology Analysis: Report covers specific technologies relevant to Cancer Biopsy. It assesses the current state, advancements, and potential future developments in Cancer Biopsy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Cancer Biopsy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Cancer Biopsy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Tissue Biopsies
Liquid Biopsies
Others
麻豆原创 segment by Application
Breast Cancer
Colorectal Cancer
Cervical Cancers
Lung Cancers
Prostate Cancers
Skin Cancers
Blood Cancers
Kidney Cancers
Others
麻豆原创 segment by players, this report covers
Qiagen N.V.
Illumina, Inc.
ANGLE Plc
Myriad Genetics
Hologic, Inc.
Biocept, Inc.
Thermo Fisher Scientific, Inc.
Danaher
Lucence Diagnostics Pte. Ltd.
GRAIL, Inc.
Guardant Health
Exact Sciences Corporation
Freenome Holdings, Inc.
Oncimmune
Chronix Biomedical, Inc.
Personal Genome Diagnostics Inc.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cancer Biopsy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cancer Biopsy, with revenue, gross margin and global market share of Cancer Biopsy from 2019 to 2024.
Chapter 3, the Cancer Biopsy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Cancer Biopsy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Biopsy.
Chapter 13, to describe Cancer Biopsy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Cancer Biopsy
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Cancer Biopsy by Type
1.3.1 Overview: Global Cancer Biopsy 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Cancer Biopsy Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Tissue Biopsies
1.3.4 Liquid Biopsies
1.3.5 Others
1.4 Global Cancer Biopsy 麻豆原创 by Application
1.4.1 Overview: Global Cancer Biopsy 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Breast Cancer
1.4.3 Colorectal Cancer
1.4.4 Cervical Cancers
1.4.5 Lung Cancers
1.4.6 Prostate Cancers
1.4.7 Skin Cancers
1.4.8 Blood Cancers
1.4.9 Kidney Cancers
1.4.10 Others
1.5 Global Cancer Biopsy 麻豆原创 Size & Forecast
1.6 Global Cancer Biopsy 麻豆原创 Size and Forecast by Region
1.6.1 Global Cancer Biopsy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Cancer Biopsy 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Cancer Biopsy 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Cancer Biopsy 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Cancer Biopsy 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Cancer Biopsy 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Cancer Biopsy 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Qiagen N.V.
2.1.1 Qiagen N.V. Details
2.1.2 Qiagen N.V. Major Business
2.1.3 Qiagen N.V. Cancer Biopsy Product and Solutions
2.1.4 Qiagen N.V. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Qiagen N.V. Recent Developments and Future Plans
2.2 Illumina, Inc.
2.2.1 Illumina, Inc. Details
2.2.2 Illumina, Inc. Major Business
2.2.3 Illumina, Inc. Cancer Biopsy Product and Solutions
2.2.4 Illumina, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Illumina, Inc. Recent Developments and Future Plans
2.3 ANGLE Plc
2.3.1 ANGLE Plc Details
2.3.2 ANGLE Plc Major Business
2.3.3 ANGLE Plc Cancer Biopsy Product and Solutions
2.3.4 ANGLE Plc Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 ANGLE Plc Recent Developments and Future Plans
2.4 Myriad Genetics
2.4.1 Myriad Genetics Details
2.4.2 Myriad Genetics Major Business
2.4.3 Myriad Genetics Cancer Biopsy Product and Solutions
2.4.4 Myriad Genetics Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Myriad Genetics Recent Developments and Future Plans
2.5 Hologic, Inc.
2.5.1 Hologic, Inc. Details
2.5.2 Hologic, Inc. Major Business
2.5.3 Hologic, Inc. Cancer Biopsy Product and Solutions
2.5.4 Hologic, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Hologic, Inc. Recent Developments and Future Plans
2.6 Biocept, Inc.
2.6.1 Biocept, Inc. Details
2.6.2 Biocept, Inc. Major Business
2.6.3 Biocept, Inc. Cancer Biopsy Product and Solutions
2.6.4 Biocept, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Biocept, Inc. Recent Developments and Future Plans
2.7 Thermo Fisher Scientific, Inc.
2.7.1 Thermo Fisher Scientific, Inc. Details
2.7.2 Thermo Fisher Scientific, Inc. Major Business
2.7.3 Thermo Fisher Scientific, Inc. Cancer Biopsy Product and Solutions
2.7.4 Thermo Fisher Scientific, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Thermo Fisher Scientific, Inc. Recent Developments and Future Plans
2.8 Danaher
2.8.1 Danaher Details
2.8.2 Danaher Major Business
2.8.3 Danaher Cancer Biopsy Product and Solutions
2.8.4 Danaher Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Danaher Recent Developments and Future Plans
2.9 Lucence Diagnostics Pte. Ltd.
2.9.1 Lucence Diagnostics Pte. Ltd. Details
2.9.2 Lucence Diagnostics Pte. Ltd. Major Business
2.9.3 Lucence Diagnostics Pte. Ltd. Cancer Biopsy Product and Solutions
2.9.4 Lucence Diagnostics Pte. Ltd. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Lucence Diagnostics Pte. Ltd. Recent Developments and Future Plans
2.10 GRAIL, Inc.
2.10.1 GRAIL, Inc. Details
2.10.2 GRAIL, Inc. Major Business
2.10.3 GRAIL, Inc. Cancer Biopsy Product and Solutions
2.10.4 GRAIL, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 GRAIL, Inc. Recent Developments and Future Plans
2.11 Guardant Health
2.11.1 Guardant Health Details
2.11.2 Guardant Health Major Business
2.11.3 Guardant Health Cancer Biopsy Product and Solutions
2.11.4 Guardant Health Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Guardant Health Recent Developments and Future Plans
2.12 Exact Sciences Corporation
2.12.1 Exact Sciences Corporation Details
2.12.2 Exact Sciences Corporation Major Business
2.12.3 Exact Sciences Corporation Cancer Biopsy Product and Solutions
2.12.4 Exact Sciences Corporation Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Exact Sciences Corporation Recent Developments and Future Plans
2.13 Freenome Holdings, Inc.
2.13.1 Freenome Holdings, Inc. Details
2.13.2 Freenome Holdings, Inc. Major Business
2.13.3 Freenome Holdings, Inc. Cancer Biopsy Product and Solutions
2.13.4 Freenome Holdings, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Freenome Holdings, Inc. Recent Developments and Future Plans
2.14 Oncimmune
2.14.1 Oncimmune Details
2.14.2 Oncimmune Major Business
2.14.3 Oncimmune Cancer Biopsy Product and Solutions
2.14.4 Oncimmune Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Oncimmune Recent Developments and Future Plans
2.15 Chronix Biomedical, Inc.
2.15.1 Chronix Biomedical, Inc. Details
2.15.2 Chronix Biomedical, Inc. Major Business
2.15.3 Chronix Biomedical, Inc. Cancer Biopsy Product and Solutions
2.15.4 Chronix Biomedical, Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Chronix Biomedical, Inc. Recent Developments and Future Plans
2.16 Personal Genome Diagnostics Inc.
2.16.1 Personal Genome Diagnostics Inc. Details
2.16.2 Personal Genome Diagnostics Inc. Major Business
2.16.3 Personal Genome Diagnostics Inc. Cancer Biopsy Product and Solutions
2.16.4 Personal Genome Diagnostics Inc. Cancer Biopsy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Personal Genome Diagnostics Inc. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Cancer Biopsy Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Cancer Biopsy by Company Revenue
3.2.2 Top 3 Cancer Biopsy Players 麻豆原创 Share in 2023
3.2.3 Top 6 Cancer Biopsy Players 麻豆原创 Share in 2023
3.3 Cancer Biopsy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Cancer Biopsy 麻豆原创: Region Footprint
3.3.2 Cancer Biopsy 麻豆原创: Company Product Type Footprint
3.3.3 Cancer Biopsy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Cancer Biopsy Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Cancer Biopsy 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Cancer Biopsy Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Cancer Biopsy 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Cancer Biopsy Consumption Value by Type (2019-2030)
6.2 North America Cancer Biopsy Consumption Value by Application (2019-2030)
6.3 North America Cancer Biopsy 麻豆原创 Size by Country
6.3.1 North America Cancer Biopsy Consumption Value by Country (2019-2030)
6.3.2 United States Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Cancer Biopsy Consumption Value by Type (2019-2030)
7.2 Europe Cancer Biopsy Consumption Value by Application (2019-2030)
7.3 Europe Cancer Biopsy 麻豆原创 Size by Country
7.3.1 Europe Cancer Biopsy Consumption Value by Country (2019-2030)
7.3.2 Germany Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biopsy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Cancer Biopsy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Cancer Biopsy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Cancer Biopsy Consumption Value by Region (2019-2030)
8.3.2 China Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Cancer Biopsy Consumption Value by Type (2019-2030)
9.2 South America Cancer Biopsy Consumption Value by Application (2019-2030)
9.3 South America Cancer Biopsy 麻豆原创 Size by Country
9.3.1 South America Cancer Biopsy Consumption Value by Country (2019-2030)
9.3.2 Brazil Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biopsy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Cancer Biopsy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Cancer Biopsy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Cancer Biopsy Consumption Value by Country (2019-2030)
10.3.2 Turkey Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Cancer Biopsy 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Cancer Biopsy 麻豆原创 Drivers
11.2 Cancer Biopsy 麻豆原创 Restraints
11.3 Cancer Biopsy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Cancer Biopsy Industry Chain
12.2 Cancer Biopsy Upstream Analysis
12.3 Cancer Biopsy Midstream Analysis
12.4 Cancer Biopsy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Qiagen N.V.
Illumina, Inc.
ANGLE Plc
Myriad Genetics
Hologic, Inc.
Biocept, Inc.
Thermo Fisher Scientific, Inc.
Danaher
Lucence Diagnostics Pte. Ltd.
GRAIL, Inc.
Guardant Health
Exact Sciences Corporation
Freenome Holdings, Inc.
Oncimmune
Chronix Biomedical, Inc.
Personal Genome Diagnostics Inc.
听
听
*If Applicable.
